CONNECT 2024 | Naturopathic Treatment of Moderately Severe Chronic Kidney Disease | Eric Yarnell, ND, RH(AHG)




Cost: Non-members: $97.50 | Member: $52.50 | Student: $22.50

There is little conventional therapy available for patients with CKD stages G3b and 4 (eGFR 15–45). This is a crucial period to prevent progression to dialysis or transplant. Naturopathic medicine has much to offer such patients, and Dr. Yarnell has had excellent success preventing progression, and sometimes even improving kidney function. The full range of testing necessary to monitor all kidney functions will be reviewed. The importance of determining and treating the cause of the kidney failure will be emphasized. Non-specific but effective natural therapies to protect and restore kidney function will be reviewed. The use of a vegetarian diet as a general therapeutic approach will be discussed, as opposed to the non-evidence-based low-protein, low-nutrient conventional diet. Learn what drugs are needed and how to use natural therapies with drugs commonly used in later stages of CKD. Case studies will be used to illustrate the possibilities.

Eric Yarnell, ND, RH(AHG) (Bastyr University, 1996) is chief medical officer at Northwest Naturopathic Urology. He has been in practice for 30 years, primarily in the fields of men’s health, urology, and nephrology, with an emphasis on botanical medicine. Dr. Yarnell is chief creative officer of Wild Brilliance Press, vice president of Heron Botanicals, and CEO of Red Root Pharmaceuticals. He previously served as chair of the department of botanical medicine at SCNM, was full professor at Bastyr, and helped edit the Journal of Naturopathic Medicine. His published works include Clinical Botanical Medicine 2nd ed, Natural Approach to Urology 2nd ed, Natural Approach to Prostate Conditions 2nd ed, and Natural Approach to Gastroenterology 2nd ed. He has received the AANP's Vis Award (2014), GastroANP's Borborygmus Award (2020), and NMSA’s Faculty of the Year Award (2018 and 2020).


**This presentation is worth 1.5 Category 1 CE, including 1 pharmacology credit, for Washington-licensed NDs.**

Originally presented May 3rd - 5th, 2024, at WANP's CONNECT 2024 conference.